Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma

Article

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy (NACT).

“High-grade serous carcinoma [HGSC] has a high degree of heterogeneity,” wrote study authors led by Rebecca C. Arend, MD, of the University of Alabama at Birmingham, in a presentation delivered at the Society of Gynecologic Oncology (SGO) Annual Meeting in National Harbor, Maryland. Chemotherapy generally can affect gene expression profiles, and NACT offers a unique opportunity to evaluate before and after therapy.

The new study was designed to evaluate those genetic variations in ovarian HGSC, as well as to assess the utility of using cell-free DNA (cfDNA) to monitor changes in gene expression. A total of 19 patients with a median age of 74 years had plasma drawn and underwent a tissue biopsy at the time of diagnosis, followed by 3 to 6 cycles of NACT, after which plasma was drawn again and patients underwent resection.

Among the most commonly mutated pathways from before to after NACT were immune signaling, cell proliferation, and cell-to-cell signaling. The most frequently upregulated genes were NR4A3 (P = 4 × 10-6), NR4A1 (P = 2 × 10-5), THBS4 (P = 6 × 10-3), SFRP2 (P = 1 × 10-2), and others. Commonly downregulated genes included E2F1 (P = .002), BRCA2 (P = .003), TTK (P = .002), and several others.

There were some differences with regard to which mutations were found more commonly in tumor samples and in plasma. For example, in the pre-NACT samples, TP53 mutations were more common in tumor than in plasma, while plasma samples showed a wider range of infrequently mutated genes, including ERBB4, ATM, BRAF, and others. After NACT, most of the mutations found in cfDNA did not persist (6 of 57 found pre-NACT); in contrast, 33 of 38 mutations in tumor DNA remained unchanged after NACT.

In spite of those differences, Arend said the study showed the feasibility of using plasma to identify tumor mutations, and the increased mutational diversity in NACT may provide a more complete picture of genetic changes. “Understanding the effect of chemotherapy on gene expression profiles may help guide therapy,” Arend noted in her presentation. “Plasma cfDNA could provide a non-invasive approach of monitoring tumor mutations.”

Recent Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content